title: [Incretin as a Novel Treatment Strategy for NAFLD/NASH].
abstract: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been recognized as metabolic disorders characterized by fatty accumulation in the liver without alcohol consumption. The diseases can cause metabolic syndromes, consisting of obesity, diabetes mellitus (DM), dyslipidemia and hypertension. For the treatment of NAFLD/NASH, losing weight by exercise or diet remains the standard treatment, because no effective pharmacological therapy has yet been developed for NAFLD/NASH. Two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), stimulate glucose-mediated insulin production in pancreatic β cells. Incretin has also been reported to have various extra-pancreatic effects, including the regulation of hepatic glucose production, appetite and satiety, as well as the stimulation of afferent sensory nerves. Therefore, incretin may have potential as a novel therapeutic agent for NAFLD/NASH.
authors.affiliation: Department of Clinical Pharmacy and Pharmacology, Kagoshima University Hospital.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Takeda
authors.forename: Ryuji
authors.initials: R
authors.lastname: Ikeda
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kondo
mesh_terms: D001066:Appetite / Q000187:drug effects; D005749:Gastric Inhibitory Polypeptide / Q000494:pharmacology / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology / Q000627:therapeutic use; D005947:Glucose / Q000378:metabolism; D006801:Humans; D054795:Incretins / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000378:metabolism; D008099:Liver; D009475:Neurons, Afferent / Q000187:drug effects; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*; D012528:Satiety Response / Q000187:drug effects; D011984:Sensory Receptor Cells / Q000187:drug effects
chemical_list: D054795:Incretins; D007328:Insulin; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005947:Glucose